EMR 3738 CTO (therapeutiC Targeting in Onclogy)
- PhD Student
2011 - 2014Mathematical modeling of serum tumor markers kinetics
- Prediction of tumor size changes induced by chemotherapy using mathematical modeling of CA-125 kinetics in recurrent ovarian cancer patients:
In advanced recurrent ovarian cancer (ROC) patients, imaging is not accurate for evaluating tumor burden changes during chemotherapy. Serum CA-125 kinetics may be used to predict tumor size changes if a relationship can be established.
Using a semi-mechanistic model, the relationships between CA-125 kinetics and tumor size changes induced by chemotherapy were established in ROC patients. A modeling approach allowed CA-125 to be assessed as a biomarker for tumor size dynamics, to predict treatment efficacy for research and clinical purposes.
- Benefit in Progression-Free survival expected from CA-125 reduction at week 6 in recurrent ovarian cancer patients using a statistical model:
Early prediction of the expected benefit in treated recurrent ovarian cancer (ROC) patients may help for drug development decisions. We used mathematical and statistical modeling to quantify the links between CA-125 kinetics, tumor size changes and progression-free survival (PFS) in ROC patients.
This is the first parametric survival model quantifying links between PFS and CA-125 kinetics in ROC patients. Patients should achieve at least 55% ΔCA125 decrease induced by treatment to observe 50% PFS improvement, independently on treatment arm. On the basis of individual ΔCA125, patients could be categorized across responders/non-responders. It may be a predictive marker of the expected gain in PFS, and may embody an early predictive tool for drug development decisions.
- Modeling of Circulating Tumor Cells (CTCs) kinetics in prostate cancer patients
EMR 3738 CTO (therapeutiC Targeting in Onclogy)
- Master Thesis
2011 - 2011Mathematical modeling of tumor size and CA-125 kinetics in relapsed ovarian cancer patients
Ovarian cancer is associated with the highest mortality rate among all invasive cancers of the female gynecological system in the world. Indeed, the majority of ovarian cancer's patients presents with advanced stage of disease at the time of diagnosis, and most of them experience recurrence. It explains the poor prognosis of this cancer. CA-125 (Cancer Antigen) is used as a biomarker for epithelial ovarian cancer, representing 90% of all ovarian cancers' types. The aim of this work is to characterize CA-125 and tumor size kinetics using a K-PD model with a population non-linear mixed-effects modeling approach.
A joint model for describing CA-125 and tumor size profiles was built, and some covariates were found, in relapsed ovarian cancer patients receiving chemotherapy. This K-PD model is the first characterizing CA-125 and tumor size variations. However, it should be improved to be useful in clinical practice.
EMR 3738 CTO (therapeutiC Targeting in Onclogy)
- Master Thesis
2010 - 2010Toxico-genomic study of dose-effect from rats exposed to 1-3 dinitrobenzene
I participated in an European project, which studying male reproductive health and endocrine toxicity. The main objectives of my internship were to analyse testicular toxicity, induced by 1, 3 Dinitrobenzene (or DNB, a testicular toxicant used in explosives preparation), on adult rats genes, to estimate the dose modifying gene expression, called Benchmark Dose (BMD), and the BMD lower condence limit (BMDL).
This work allowed to describe a method, which can be used to study the toxicity of any molecules, in order to characterizing the Benchmark Dose for a large set of genes resulting from DNA chips. In prospect, each signicant gene should be study, in order to understand their functions in cellular processes.
